Press Releases/ Announcement
輝能與 TDAC 宣布 1.35 億美元潛在投資案
Press Information
Nov 20, 2026
- 簽署非具約束力投資意向書,擬投資金額最高達 1.35 億美元
- 既有及策略投資人擬於企業合併交易完成時,以每股 10 美元參與投資
- 預計投資所得將用於推進法國敦克爾克超級工廠建置,朝首階段 4 GWh 產能目標邁進,並拓展新市場營收機會及其他一般企業營運用途
【台灣台北、美國紐約,2026 年 11 月 20日】次世代鋰陶瓷電池技術全球領導廠商輝能科技(ProLogium Holding Inc.,以下簡稱「輝能」或「本公司」)與特殊目的收購公司 Translational Development Acquisition Corp.(Nasdaq:TDAC,以下簡稱「TDAC」)今日共同宣布,雙方已與多家既有投資人及策略投資人簽署非具約束力的投資意向書,擬議投資總額最高達 1.35 億美元。
根據投資意向書,輝能既有投資人及其他策略投資人已表達投資意願,預計將配合輝能先前宣布與 TDAC 規劃中的企業合併交易(以下簡稱「本交易」)進行投資。各項 PIPE(上市公司私募投資)預計將於本交易交割時,以每股 10 美元認購普通股。其中一份與策略合作夥伴簽署的意向書,亦規劃於本交易交割後進行後續投資,具體條件將納入雙方合作計畫中進一步協商。
上述擬議投資仍須進一步協商並簽署正式交易文件。輝能預計將運用相關資金推進法國敦克爾克超級工廠建置,並持續取得法國政府 15 億美元補助計畫的核撥款項;同時加速拓展無人機等新興應用領域,開發新市場營收機會,並支應其他一般企業營運用途。本交易預計於 2026 年 12 月完成交割,惟仍須取得 TDAC 股東核准及符合其他慣常交割條件。
輝能創辦人暨執行長楊思枏表示:「此次投資意向書反映投資人對輝能技術的高度關注、以及我們擴大次世代鋰陶瓷電池產能計畫的認同。新增資金將有助於加速法國敦克爾克超級工廠的建置,並支持我們持續拓展電動車、無人系統、AI 資料中心及其他多元應用市場,進一步服務歐洲及全球客戶。」
TDAC 董事長暨執行長 Michael B. Hoffman 表示:「我們樂見此次投資意向書所展現的既有投資人及策略投資人支持。目前正與相關投資人合作,推進正式協議的定案,並朝本交易交割目標邁進。」
.
顧問團隊
Cohen & Company Capital Markets(Cohen & Company Securities, LLC 旗下部門)擔任輝能集團之獨家財務顧問、首席資本市場顧問及配售代理;Credit Agricole Securities (USA) Inc.(及其關係企業,包括 Crédit Agricole Corporate and Investment Bank)擔任輝能集團之配售代理;Sullivan & Cromwell LLP 與 LCS & Partners 擔任輝能集團之法律顧問。
BTIG, LLC 擔任 TDAC 之獨家財務顧問、首席資本市場顧問及配售代理;Venable 擔任 TDAC 之法律顧問。
關於輝能
輝能集團(ProLogium Group)成立於 2006 年,是一家專注於次世代鋰陶瓷電池研發與製造的能源創新企業,全球累計擁有超過 1,200 件專利及專利申請,涵蓋已核准專利與申請中專利。
2013 年,輝能成功將固態電池技術商業化,產品初期主要應用於智慧型手機充電配件。自 2013 年以來,輝能已累計向合作夥伴及客戶出貨超過 240 萬顆電池,應用涵蓋車載音響系統等領域,並提供約 10,000 顆汽車應用電池樣品。
2025 年,輝能推出「超流體化無機次世代鋰陶瓷電池」,整合固態與液態電池技術的優勢,兼具規模化量產能力與成本競爭力。該技術於 2026 年再度獲得愛迪生獎金獎肯定。
憑藉超過 13 年的製造技術與量產經驗,輝能是全球唯一能公開展示次世代電池量產線的企業,展現次世代電池已從實驗室研發邁向成熟的規模化製造。輝能亦是業界率先成功商業化高效率捲對捲陶瓷隔離層塗佈製程的企業之一。
輝能的首座 GWh 級超級工廠位於台灣桃園。2024 年,輝能於法國巴黎薩克雷(Paris-Saclay)設立首座海外研發中心,提供歐洲市場客製化技術支援。第二座電池超級工廠位於法國敦克爾克,第一期工程已於 2026 年 2 月舉行動土典禮,目前持續推進細部設計與建置。第一期完工後,年設計產能將達 4.0 GWh,預計於 2030 年逐步達成;敦克爾克廠區整體最高設計產能則可達 44.0 GWh,並將與巴黎薩克雷研發中心緊密合作。
2026 年 5 月,輝能與 Translational Development Acquisition Corp.(Nasdaq:TDAC)簽署正式企業合併協議,並已向美國證券交易委員會(SEC)提交 F-4 註冊聲明。依目前交易架構,待企業合併完成、取得相關核准並符合上市條件後,輝能預計將於 Nasdaq 掛牌上市,股票代號為 PRLG。
關於 TDAC
Translational Development Acquisition Corp.(TDAC)是一家特殊目的收購公司(SPAC),成立宗旨是透過合併、公司合併、股份交換、資產收購、股份購買、重組或其他類似企業合併方式,與一家或多家企業完成業務合併。
TDAC 可於任何企業、產業、領域或地理區域尋求收購機會,並計畫聚焦於與其管理團隊專業背景互補的產業,同時運用管理團隊在識別及收購企業方面的專業能力。
關於本交易案的重要資訊及如何取得 Important Information and Where to Find It
In connection with the Transaction, ProLogium has filed a registration statement on Form F-4 with the SEC that includes a prospectus with respect to ProLogium’s securities to be issued in connection with the Transaction and a proxy statement with respect to the shareholder meeting of TDAC to vote on the Transaction. This communication, including the investment described herein, does not contain all the information that should be considered concerning the Transaction and is not intended to form the basis of any investment decision or any other decision in respect of the Transaction. Before making any voting or investment decision, shareholders of TDAC, investors and other interested persons are advised to read carefully and in their entirety, the preliminary proxy statement / prospectus (including any amendments thereto), as well as other documents filed with the SEC, because these documents will contain important information about ProLogium, TDAC and the Transaction. After the registration statement is declared effective, the definitive proxy statement / prospectus to be included in the registration statement will be mailed to shareholders of TDAC as of a record date to be established for voting on the Transaction. The preliminary and definitive proxy statement / prospectus to be included in the registration statement, once available, can also be obtained, without charge, at the SEC’s website at www.sec.gov or by directing a request to: [email protected].
前瞻性聲明Forward-Looking Statements
This communication contains forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, or the Securities Act, and section 21E of the U.S. Securities Exchange Act of 1934, as amended, or the Exchange Act, that are based on beliefs and assumptions and on information currently available to ProLogium and TDAC. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing,” “target,” “seek” or the negative or plural of these words, or other similar expressions that are predictions or indicate future events or prospects, although not all forward-looking statements contain these words. Any statements that refer to expectations, projections or other characterizations of future events or circumstances, including the anticipated use of proceeds from the investment described herein, projections of market opportunity, number of customers or users and market share, the capability of ProLogium’s technology, ProLogium’s business plans including its plans to expand globally, the sources and uses of proceeds from the Transaction, the anticipated enterprise value of the combined company following the consummation of the Transaction, any benefits of ProLogium’s partnerships, strategies or plans as they relate to the Transaction, anticipated benefits of the Transaction and expectations related to the terms and timing of the Transaction are also forward-looking statements. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by these forward-looking statements. These statements are based on ProLogium and TDAC’s reasonable expectations and beliefs concerning future events and involve risks and uncertainties that may cause actual results to differ materially from current expectations. These factors are difficult to predict accurately and may be beyond ProLogium and TDAC’s control. Forward-looking statements in this communication or elsewhere speak only as of the date made. New uncertainties and risks arise from time to time, and it is impossible for ProLogium or TDAC to predict these events or how they may affect ProLogium or TDAC. In addition, there will be risks and uncertainties described in the proxy statement / prospectus relating to the Transaction, included in the registration statement on Form F-4 filed by ProLogium with the SEC, as amended from time to time, and other documents filed by ProLogium or TDAC from time to time with the SEC. These filings may identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Neither ProLogium nor TDAC can assure you that the forward-looking statements in this communication will prove to be accurate. These forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to: the occurrence of any event, change or other circumstances that could delay, impede or prevent the business combination or give rise to the termination of the business combination; the outcome of any legal proceedings that may be instituted against ProLogium or TDAC, the combined company or others following the announcement of the business combination; the inability to complete the business combination due to the failure to obtain approval of the shareholders of ProLogium and TDAC or of the parties to satisfy other conditions to closing; the level of redemptions by TDAC’s public shareholders; the ability to maintain the stock exchange listing standards following the consummation of the business combination; the risk that the business combination disrupts current plans and operations of ProLogium or TDAC as a result of the announcement and consummation of the business combination; the ability to recognize the anticipated benefits of the business combination; costs related to the business combination; changes in applicable laws or regulations; international trade disputes, including threatened or implemented tariffs by the U.S. and threatened or implemented tariffs by foreign countries in retaliation; the ability of ProLogium to execute its business model, including market acceptance of its planned products and services; the combined company’s ability to raise capital; future financial performance of the combined company following the business combination; the possibility that TDAC or the combined company may be adversely affected by other economic, business, and/or competitive factors; risks associated with ProLogium’s efforts to commercialize its products; ProLogium’s ability to maintain its existing agreements with third parties and to negotiate and enter into new definitive agreements on favorable terms, if at all; the impact of competing products on ProLogium’s business; intellectual property-related claims against ProLogium or the combined company; ProLogium’s dependence upon its key personnel and ability to attract and retain such personnel and additional qualified personnel; ProLogium’s ability to source the raw materials for its products; the non-binding nature of the term sheets relating to certain proposed financing arrangements described herein; the risk that definitive agreements for such financing arrangements may not be negotiated or executed on the terms contemplated or at all; and the risk that, even if definitive agreements are executed, applicable funding conditions may not be satisfied or waived and the anticipated proceeds may not be received in the amounts or within the timeframe contemplated, or at all; and other risks and uncertainties set forth in the section entitled “Risk Factors” in the registration statement on Form F-4 filed by ProLogium with the SEC and those included under the heading “Risk Factors” in the final prospectus for TDAC’s initial public offering, filed pursuant to Rule 424b(4) on December 23, 2024, and its annual report on Form 10-K for year ended December 31, 2025 and in its subsequent quarterly reports on Form 10-Q and other filings with the SEC. There may be additional risks that neither ProLogium nor TDAC presently knows or that ProLogium and TDAC currently believe are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by ProLogium, TDAC, their respective directors, officers or employees or any other person that ProLogium and TDAC will achieve their objectives and plans in any specified time frame, or at all. The forward-looking statements in this communication represent the views of ProLogium and TDAC as of the date of this communication. Subsequent events and developments may cause those views to change. Except as required by applicable law, neither ProLogium nor TDAC has any duty to, and does not intend to, update or revise the forward-looking statements in this communication or elsewhere after the date of this communication. You should, therefore, not rely on these forward-looking statements as representing the views of ProLogium or TDAC as of any date subsequent to the date of this communication.
徵求委託書之參與人Participants in Solicitation
ProLogium and TDAC and their respective directors and executive officers may be considered participants in the solicitation of proxies with respect to the Transaction described in this communication under the rules of the SEC. Information about the directors and executive officers of TDAC and their ownership is set forth in TDAC’s filings with the SEC, including TDAC’s final prospectus for its initial public offering, filed pursuant to Rule 424b(4) on December 23, 2024, its Form 10-K for the year ended December 31, 2025 and subsequent filings under section 16 of the Exchange Act or on Form 10-Q. Additional information regarding the persons who may, under the rules of the SEC, be deemed participants in the solicitation of TDAC’s shareholders in connection with the Transaction is set forth in the registration statement containing the preliminary proxy statement/prospectus filed by ProLogium with the SEC. These documents are available free of charge at the SEC’s website at www.sec.gov or by directing a request to: [email protected].
不構成要約或招攬No Offer or Solicitation
This communication is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the Transaction and does not constitute an offer to sell or a solicitation of an offer to buy any securities of ProLogium or TDAC, nor shall there be any sale of any such securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act.

